CHUGAI PHARMACEUTICAL CO., LTD.
- Country
- 🇯🇵Japan
- Ownership
- Public, Subsidiary
- Established
- 1925-03-10
- Employees
- 7.6K
- Market Cap
- $83.6B
Study of AUBE00 in Patients With Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- Drug: AUBE00
- First Posted Date
- 2025-06-22
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 100
- Registration Number
- NCT07030959
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
- Conditions
- Antiphospholipid Syndrome (APS)Bullous Pemphigoid (BP)Dermatomyositis (DM)Immune-mediated Necrotizing Myopathy (IMNM)Behçet's Syndrome (BS)Immune Thrombocytopenia (ITP)
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 144
- Registration Number
- NCT06723106
- Locations
- 🇨🇦
DiIEX Recherche Sherbrooke, Inc, Sherbrooke, Quebec, Canada
🇯🇵Okayama University Hospital, Okayama, Japan
🇦🇺Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
Phase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial)
- Conditions
- DermatomyositisImmune ThrombocytopeniaBehçet’s SyndromeAntiphospholipid syndromeImmune-mediated necrotizing myopathyBullous pemphigoid
- Interventions
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2025-04-14
- Lead Sponsor
- Chugai Pharmaceutical Co. Ltd.
- Target Recruit Count
- 87
- Registration Number
- 2023-507692-21-00
- Locations
- 🇷🇴
Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj-Napoca, Romania
🇷🇴Centrul Medical Monza S.R.L., Bucharest, Romania
🇪🇸Clinica Universidad De Navarra, Madrid, Spain
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 219
- Registration Number
- NCT05907980
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸NEXT Oncology, Fairfax, Virginia, United States
🇯🇵National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 231
- Registration Number
- NCT05735366
- Locations
- 🇺🇸
Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
🇺🇸MUSC Hollings Cancer Center, Charleston, South Carolina, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
A Decentralized Home-Based Study To Investigate Novel Objective Biomarker Of Gluten-Mediated Symptoms In Celiac Disease Participants (CeDar ROSE Study)
- Conditions
- Celiac Disease
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 12
- Registration Number
- NCT05686369
- Locations
- 🇺🇸
Science 37, Culver City, California, United States
Post-Marketing Drug Intensive Monitoring Surveillance of EDIROL in Patients With Postmenopausal Osteoporosis
- Conditions
- Postmenopausal Osteoporosis
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 1000
- Registration Number
- NCT05433207
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 56
- Registration Number
- NCT05425446
- Locations
- 🇺🇸
Pinnacle Research Group, Anniston, Alabama, United States
🇺🇸Mountain View Clinical Research, Denver, Colorado, United States
🇺🇸Jacksonville Center for Clinical Research, Jacksonville, Florida, United States
A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 179
- Registration Number
- NCT05022927
- Locations
- 🇯🇵
Chiba University Hospital, Chiba-shi, Chiba, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
- Conditions
- Locally Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 195
- Registration Number
- NCT05012618
- Locations
- 🇺🇸
University of California - Davis, Davis, California, United States
🇺🇸Beth Israel Deaconess, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States